From 24/7 Wall St. · Vandita Jadeja · · 1m 10s
Eli Lilly's $1500 Target Surprises Wall Street
Eli Lilly's revenue growth outpaces stock price, with analysts missing a $1500 target by 2027
In brief
Eli Lilly's revenue growth outpaces stock price, with analysts missing a $1500 target by 2027 Eli Lilly could reach $1500 per share by 2027 if retatrutide clears regulatory hurdles and prescriber adoption grows Originally reported by 24/7 Wall St..
Revenue Growth vs Stock Price
Eli Lilly reports 48% year-over-year revenue growth while shares trade nearly flat year to date.
48% Revenue Growth
Mounjaro and Zepbound generated $14.9 billion in Q2 revenue, with CEO David Ricks stating Lilly's future has never been brighter.
“Lilly's future, after 150 years, has never been brighter”
Stock Stalls Despite Growth
Shares dropped 9.95% in the past month after climbing 3.34% in the last week, despite strong revenue growth.
Analyst Targets
Wall Street targets $1,325.39 for Eli Lilly, implying 15% upside from current prices, but the author believes $1,500 is achievable.
Path to $1500
Reaching $1,500 requires a 30.1% gain from current prices, with key catalysts including FDA approvals for cardiovascular risk and breast cancer treatments.
Regulatory Risks
The primary risk is a regulatory delay on retatrutide's biologic classification, which could compress stock price gains instead of expanding them.
The one thing
Eli Lilly could reach $1500 per share by 2027 if retatrutide clears regulatory hurdles and prescriber adoption grows
